ANI Pharmaceuticals, Inc.
ANIP
$75.33
-$1.20-1.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 367.52% | 210.14% | 473.81% | -13.87% | -989.70% |
| Total Depreciation and Amortization | 0.06% | 43.71% | 58.41% | 55.87% | 48.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.45% | 0.61% | -18.54% | -11.62% | 1,302.87% |
| Change in Net Operating Assets | -461.43% | -314.16% | 904.35% | 113.00% | -117.21% |
| Cash from Operations | 91.47% | 253.17% | 335.35% | 91.53% | -64.55% |
| Capital Expenditure | 48.04% | -26.83% | 9.78% | 45.99% | -5.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -84.88% | 90.49% | -- | -- | 96.56% |
| Cash from Investing | 86.86% | 98.45% | -55.29% | -322.17% | -123.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.05% | 99.31% | -170.80% | -170.80% | -170.80% |
| Issuance of Common Stock | -97.76% | 721.31% | 23.58% | -2.20% | -13.66% |
| Repurchase of Common Stock | -92.14% | -53.53% | 57.62% | -15.49% | -37.66% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 100.00% | 15.27% | 0.00% | 0.00% | 0.00% |
| Other Financing Activities | 100.00% | 99.96% | -- | -- | 69.18% |
| Cash from Financing | 5.52% | -97.82% | -20.32% | 49.78% | 58.83% |
| Foreign Exchange rate Adjustments | -242.53% | 868.00% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18,778.86% | 147.13% | 490.61% | -33.90% | -100.44% |